Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting
Go back to Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting| (NASDAQ: RADX) | Delayed: 1.73 +0.06 (3.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.67 | 52 Week High | $ | |||
| Open | $1.70 | 52 Week Low | $ | |||
| Day High | $1.91 | P/E | N/A | |||
| Day Low | $1.70 | EPS | $ | |||
| Volume | 66,491 | |||||
